Overview

Inclisiran Versus Placebo for the Prevention of Major Adverse Cardiovascular and Limb Events in Patients Undergoing Percutaneous Coronary Intervention or Peripheral Endovascular Intervention

Status:
RECRUITING

Trial end date:
2029-12-01

Target enrollment:

Participant gender:

Summary

V-INTERVENTION will evaluate the effectiveness of inclisiran in preventing major cardiovascular and limb events in patients receiving percutaneous coronary or peripheral arterial revascularization. Inclisiran is a subcutaneous, twice-yearly injection that is FDA-approved as an adjunct with statin therapy and on the market to lower LDL-C in high-risk populations.

Phase:

PHASE4

Details

Lead Sponsor:

Duke University

Collaborators:

Colorado Prevention Center
Mount Sinai Hospital, New York
Novartis Pharmaceuticals

Treatments:

ALN-PCS
Saline Solution